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Abstract
Purpose Although obesity has been associated with 
improved survival on dialysis, its effects on renal 
transplantation outcomes remain unclear. Herein we aimed 
to evaluate the effect of obesity on posttransplantation 
complications.
Patients and methods A retrospective analysis of 
consecutive renal transplant recpients from un related living 
donors was undertaken from 2006 to 2008. 
Results We included 180 patients, 34 (18%) were obese 
(body mass index >30 kg/m2) and 146 were lean.Obese 
patients were more likely to develope renal artery stenosis 
(17.6% vs 2.8%, p < 0.001), hematoma (47.9% vs 17.6, 
p = 0.009), wound complications (64.7% vs 9.6%, P < 0.001) 
and renal vein thrombosis(2% vs 0%, p < 0.001). Urologic 
complications consisting ureteral, ureteropelvic and 
ureterovesicular junction stenosis, wound bleeding, urinary 
leakage and renal artery thrombosis and also hospitalization 
time were found similar between the two groups. 2 year 
patiets and graft survival were not statististically different.
Conclusions Renal transplantation could be performed 
with reasonable urologic complications in obese patients
Keywords Obesity · Urologic complications · Renal 
transplantation
Introduction
The prevalence of obesity in patients with end-stage renal 
disease (ESRD) is increasing rapidly [1, 2]. In 2003, 60% 
of the renal transplant candidates in the United States were 
either obese or overweight [3]. Kidney transplantation, in 
contradistinction to dialysis, improves the quality of life and 
adds years of life to patients with end-stage renal disease 
(ESRD) [4–6]. Although obesity has been associated with 
improved survival on dialysis in comparison to nonobese 
patients, but its effects on renal transplant outcomes remain 
unclear. Urinary complications are common following renal 
transplantation. Some authors report that the outcomes for 
obese kidney transplant recipients are inferior to those 
of non-obese recipients [7–13] whereas others report no 
difference in outcomes [14–17]. This may be related in 
part to selection of the study populations, but most reports 
do not differentiate between obese patients (BMI between 
25 and 30 kg/m2) and morbidly obese patients (BMI > 35 kg/
m2). The World Health Organization (WHO) classification 
of obesity is determined by the body mass index (BMI), 
which is defined as weight in kilograms (kg) divided 
by height in meters squared (m2). Using this calculation, 
a BMI of 18.5–24.9 kg/m2 represents normal weight, 
a BMI of 25–29.9 kg/m2 represents overweight, and a 
BMI greater than 30 kg/m2 represents obesity. Obesity 
affects at least 20% of the adult population in developed 
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countries and its incidence is continuing to increase [18]. 
The aim of this study is to evaluate the impact of recipients 
obesity on urologic complications in unrelated living donor 
kidney transplants.
Patients and methods
An analytic file was created from the United Network 
for Organ Sharing (UNOS) Standard Transplant and 
Research (STAR) files based on OPTN data as of July 
16, 2004. We identified all patients over 15 years old who 
underwent open nephrectomy unrelated living donor 
kidney transplantation from April 2006 to January 2008. 
Exclusion criteria included multiorgan transplantation 
or a history of prior renal transplantation and age 
<15 years old, leaving a total of 180 persons classified 
as non-obese (lean) or obese. End to-end arterial 
anastomosis was performed between renal transplanted 
artery and the internal iliac artery. The renal vein was 
anastomosed to external iliac vein with an End-to-side 
anastomosis. The ureters were anastomosed by using 
anterior Lich technique and stenting was carried out 
in all ureters which were removed after two weeks. 
A triple immunosuppressive protocol therapy including 
Cyclosporine, Mycophenolate Mefotil, and Prednisolone 
was administred for all recipients.
The patients were followed for two years. In the data-
base information was stored about recipient age and sex, 
donor age and sex, vascular complications, lymphocoel, 
haemorrhage, urinary leakage and ureteral stenosis, wound 
complications (infections and dehiscences), delayed graft 
function (DGF); (defined as the need for dialysis in the first 
week after renal transplantation) and BMI at the time of 
transplantation.
Statistical analysis
Data were shown as means ± SD. Graft survival was evalu-
ated by the Kaplan–Meier method. Univariate comparison 
between Kaplan–Meier curves of the two groups was evalu-
ated by Breslow statistics and log rank analysis. The sta-
tistical significance of differences between proportions was 
determined by chi-square analysis with Yates correction. 
Significance was defined as p < 0.05.
Results
During 2-year period between April 2006 and January 
2008, among 180 patients underwent transplantation in this 
historical cohort, 34 (18%) were obese (body mass index 
[BMI]> 30 kg/m2) and 146 (82%) were non-obese(body 
mass index [BMI]< 30 kg/m2). The mean BMI in the lean 
and obese recipients were 26.4 kg/m2 (range 18.2–29.4) 
and 32.7 kg/m2 (30.3–34.8), respectively. There were 
70 women (39%) and 110 men (61%) underwent renal 
trasplantation. Mean age of recipients and donors were 
39.8  ± 14.9 (ranged 15 to 77) and 29.3 ± 6.2 years old 
(ranged 21 to 34), respectively. All of our living kidney 
donors were HLA-mismatched unrelated donors. Patients’ 
demographic characteristics are shown in Table 1. Older 
recipients were related to experience more risk for 
renal artery stenosis and hematoma (p = 0.002 and 0.03 
respectively). Obese patients were more likely to experience 
renal artery stenosis (RAS) (17.6% vs 2.8%, P < 0.001). 
Logistic regression model showed a significant difference 
for the evaluation of BMI as a risk factor for hematoma 
(17.6% vs 48%, p = 0.009) and wound complications 
(64.7% vs 9.6%, p < 0.001) also there were a significant 
difference of renal vein thrombosis (RVT) between obese 
(2%) and non-obese group in which none of the patients 
had renal vein thrombosis (p < 0.05). As demonstrated 
in Table 2 there were no significant differences between 
the two groups with respect to DGF, ureteropelvic 
obstruction, UVJ obstruction, wound bleeding and urinary 
leakage, renal artery thrombosis and hospitalization time 
(p=No significant). During 2-year follow up no deaths had 
been observed in recipients. Graft survival rate in the obese 
patients was not significantly lower than that in lean kidney 
recipients (94.1% vs 96.7%; P = .42)
Table 1 Baseline characteristics of overweight (body mass index >30kg/m2 at the time of transplantation) and non-overweight renal 
transplant recipients
BMI
Demographic factors [BMI] > 30 kg/m2 [BMI]< 30 kg/m2
Total 34 (18%) 146 (82%)
Sex (%)
 Male 17 (50%) 93 (63.7%)
 Female 17 (50%) 53 (36.7%)
Age ± SD (yr) (age range) 45.2 ± 5.4 (40.2–50.2) 38.6 ± 4 (38.2–41)
Hypertention 8 (23.5%) 30 (20.5%)
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Discussion
During last two decades the prevalence of obese patients 
undergoing renal transplantation has more than doubled, 
while about 60% of patients currently on the waiting list for 
a transplant are obese [3]. 
The impact of recipient obesity on patient and graft 
survival is controversial; Some reports described BMI as 
a putative independent risk factor for patient mortality 
and graft failure independent of patient death after renal 
transplantation [19]. Some investigators have demonstrated 
no association between obesity and adverse graft survival, 
despite the increased risk among obese recipients for wound 
infections and DGF [12–16].
We observed a significant association between body 
mass index and the surgical renal transplant outcomes, 
especially vascular complications, such as renal artery 
stenosis, renal vein thrombosis and hematoma in the 
current analysis involving 180 adult Iranian patients 
followed at a single center study. Apart from mentioned 
surgical complications which were related to vascular 
complications, obesity was not associated with short or long 
term post transplant urologic complications such as ureter 
obstruction, ureteropelvic obstruction, UVJ obstruction, 
bleeding and leakage, renal artery thrombosis or increase 
in hospitalization time as like as D. Singh et al, detected no 
association between obesity with major short or long term 
posttransplant complications but obese patients were more 
likely to remain in hospital after transplantation [20]. Our 
findings showed obese recipients were prone to experience 
wound complications (infection and dehiscence) which 
were similar to Johnson et al. [21] who have reported 
increase in wound complications. In their retrospective 
study hospitalization time were also similar between the 
two groups which were in concordance with our results. 
Kasiske and colleagues reported age, African-American 
race, Hispanic ethnicity, male donor, increasing human 
leukocyte antigen (HLA) mismatches, HCV infection, 
BMI greater than 30 kg/m2, and tacrolimus as the initial 
maintenance immunosuppressive drug could be proposed 
as risk factors for post transplant diabetes mellitus (PTDM) 
after transplantation [22]. Immunosuppressive drugs have 
an important role in the development of PTDM. The authors 
recommended a less diabetogenic immunosuppressive 
protocol, especially for older recipients [23].
Recently an experience in our center by Savaj et al, have 
described an Overall of 19.2% recipients developed PTDM 
during 24 posttransplant months [23]. In the mentioned 
study recipient’s weight and gender, the donor’s age and 
gender were not the risk factors of PTDM in our previous 
study. The 5-year patient and graft survival rates were not 
significantly different between the kidney recipients with 
and without PTDM [23]. 
Obesity itself is a risk factor for cardiovascular disease 
in the general population and it would be possible that 
pretransplant obesity might result in reduced patient survival 
by association with cardiovascular death. The effect of 
pretransplant obesity on patient survival is conflicting. 
studies have shown a significant difference in patient 
survival but on the other hand some studies have shown no 
difference [24, 25].
Herein we did not detect significant differences in either 
patient and graft survival rates or DGF in obese and non 
obese recipients. Similarly, Merion et al. [15] described 
greater incidence of wound infections in obese populations 
while other parameters including the patients and graft 
survival rates were the same. Similar findings were also 
observed by Drafts et al. [16]. On the other hand some have 
Table 2 Univariate analysis of recipient BMI and post-operative graft outcome
[BMI]> 30 kg/m² [BMI]< 30 kg/m²
Renal artery stenosis (%) 17.6% 2.8%*
Hematoma (%) 48% 17.6%**
Wound complications (%) 64.7% 9.6%*
Renal vein thrombosis 2% 0%***
Wound bleeding 0% 0%
UVJ obstruction 0% 0%
urinary leakage 2.9% 0.7%
renal artery thrombosis 2.9% 0%
Ureteropelvic obstruction 3(8.8%) 11(7.5%)
DGF 3(8.8%) 10(6.8%)
2-year patients survival 100% 100%
2-year Graft survival 94.1% 96.7%
Hospitalization time (day) 18.2 ± 3.6 (14–23) 15.1 ± 2.3(12–19)
UVJ, Ureterovesical Junction
*p< 0.001 vs. overweight          **p= 0.009 vs. overweight          ***p< 0.05 vs. overweight
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revealed association between obesity and posttransplant 
complications containing, graft survival [19], urological 
complication and DGF [26]. This disparity might be 
caused by improvement in patient management and 
transplant outcomes over the time. Herein we did not sub 
analyze recipients with morbid obesity (BMI > 35 kg/m2) 
and we did not investigate the incidence of PTDM or 
cardiovascular complications and comorbidities which 
could be limitations of our study. According to Marks et 
al kidney transplantation can be performed for morbidly 
obese patients safely with patient and graft survival time 
similar to nonobese recipients, at least for the first 3 post-
transplant years [25]. Although higher BMI is associated 
with a survival advantage on dialysis, it is revealed that 
kidney transplantation provides obese patients a survival 
advantage over dialysis as reported by Glanton et al. [6] 
and Marks et al. [27].
Conclusions
Obesity is not considered as contra-indication for renal 
transplantation and renal transplantation could be performed 
with reasonable urologic complications in obese patients 
with acceptable transplantation complications and graft 
survival in comparison with non obese patients.
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